Fujirebio

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Biometrics, Other Health, Health, Other Science, Science, Neurodegenerative disease, Fujirebio, DirectX, Partnership, Patient, Biomarker, RUO, IVD, Beckman Coulter, Apolipoprotein E, Therapy, Physician, AFL, Amyloid, Medical imaging

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer’s disease therapeutics.
  • These new assays are being developed for use on the recently introduced Beckman Coulter DxI 9000 Immunoassay Analyzer.
  • Kevin O’Reilly, President, Beckman Coulter Diagnostics, commented, “We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream.”
    “Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world,” stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. “We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide.”

Beckman Coulter and Fujirebio Expand Partnership to Develop Patient-friendly, Blood-based Neurodegenerative Disease Diagnostics

Retrieved on: 
Tuesday, March 12, 2024
Neurodegenerative disease, Health, Fujirebio, DirectX, Partnership, Patient, Biomarker, Research, RUO, IVD, Beckman Coulter, Apolipoprotein E, Analyser, Therapy, Physician, AFL, Amyloid

BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.

Key Points: 
  • BREA, Calif. and TOKYO, March 12, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced an expansion of their partnership focused on development, manufacturing and clinical adoption of neurodegenerative disease assays.
  • In 2023, Beckman Coulter and Fujirebio entered into a collaboration agreement focused on new biomarkers aligned with recently approved monoclonal antibody-based Alzheimer's disease therapeutics.
  • Kevin O'Reilly, President, Beckman Coulter Diagnostics, commented, "We are very excited by our expanded partnership with Fujirebio designed to overcome challenges of developing highly sensitive assays, measuring ultra-low concentrations of neurodegenerative disease biomarkers circulating in the blood stream."
  • "Our expanded partnership with Beckman Coulter will enable increased laboratory, clinician and patient access to more neurodegenerative biomarkers around the world," stated Monte Wiltse, President & CEO, Fujirebio Diagnostics, Inc. "We look forward to continued collaboration with Beckman Coulter bringing these critical assays to physicians and patients worldwide."

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Fujirebio and Sysmex Sign Agreement for the Supply of Reagent Raw Materials in the Field of Immunoassay

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, General Health, Biometrics, Health, Pharmaceutical, Antibody, Risk, Growth, Fujirebio, Sysmex Corporation, Antigen, Agreement, Immunoassay, CDMO

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have signed an agreement for the mutual supply of reagent raw materials owned by both companies (“the Agreement”).
  • The Agreement is based on a basic agreement on business collaboration in the field of immunoassay*1 which the two companies signed in October 2023.
  • In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, in a bid to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay.
  • Under the terms of the Agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, mainly antigens and antibodies, which are the main raw materials of immunoassay reagents.

Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Retrieved on: 
Thursday, November 30, 2023
Health, Biometrics, Other Health, General Health, Pharmaceutical, Biotechnology, Fujirebio, Sysmex Corporation, CSF, Disease, Basic, Alzheimer's disease, Immunoassay, Partnership, CDMO, Pharmaceutical industry

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

Key Points: 
  • Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa) and Sysmex Corporation (President: Kaoru Asano) today announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization (CDMO) partnership for Sysmex's Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.
  • Under the terms of the new agreement, in the field of neurodegenerative diseases including Alzheimer's Disease, Fujirebio will develop reagents for Sysmex's HISCL™-Series for cerebral spinal fluid (CSF)-based testing as well as blood-based testing.
  • This will accelerate the expansion of Sysmex’s testing parameters in the diseases field, further propelling the expansion of its global footprint in immunoassay.
  • Fujirebio and Sysmex will further collaborate to develop and launch the tests as early as possible.

Momentum in Alzheimer's Research Guided by the Biology of Aging to be Highlighted in Session Moderated by Alzheimer's Drug Discovery Foundation at 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 17, 2023
Fillit, Momentum, Drug development, Amyloid, ET, Ageing, Alzheimer's Drug Discovery Foundation, Drug, Therapy, Doctor of Philosophy, Entrepreneurship, Inflammation, Research, Emerging, Boston Park Plaza, Plasma, Denali, Medicine, Biology, Brain, Cancer, Path, Fujirebio, Alzheimer's Research UK, Pharmaceutical industry, Medical imaging, Medical device, Alzheimer's disease, MD, Disease

NEW YORK, Oct. 17, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) will be moderating a session, "Emerging Solutions: Novel Approaches to Treating Alzheimer's Disease," at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.

Key Points: 
  • This session will highlight the biology of aging and promising drugs in the pipeline that are targeting the many underlying aging pathologies contributing to the onset of Alzheimer's.
  • This is timely, as 75% of Alzheimer's drugs in clinical trials are exploring novel targets beyond amyloid and tau.
  • The session will also feature innovative research on regenerative therapies for Alzheimer's as well as novel approaches for targeting inflammation.
  • The panel will discuss the strategic investments needed to accelerate the recent momentum in the field, which is critical for fast-tracking the next generation of Alzheimer's therapeutics.

Fujirebio and Sysmex Enter into Basic Agreement on Business Collaboration in the Field of Immunoassay

Retrieved on: 
Tuesday, October 10, 2023
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Partnership, Immunoassay, Minato, LDT, Brain, Alzheimer's disease, HQ, Sysmex Corporation, Fujirebio, CDMO, Pharmaceutical industry, Medical device

Sysmex has built up a robust technological foundation as well as a global network in the in vitro diagnostics field through developing its business in this field for more than 50 years.

Key Points: 
  • Sysmex has built up a robust technological foundation as well as a global network in the in vitro diagnostics field through developing its business in this field for more than 50 years.
  • In order to further reinforce its diagnostics business, the company aims to speed up expansion of its immunochemistry business in the global markets including U.S. and Europe.
  • Fujirebio has a wide range of reagent raw materials and product portfolios through its long-standing business in the immunoassay.
  • Fujirebio and Sysmex aim to deliver high value testing to global customers as early as possible driven by strengthened partnership in immunoassay.

Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC

Retrieved on: 
Tuesday, July 25, 2023
Mayo University Hospital, Beckman Coulter, Maintenance, Medicine, Partnership, Senior, Bureau of Oceans and International Environmental and Scientific Affairs, Research, Analyser, Biomarker, DirectX, Laboratory, Patient, Risk, Fujirebio, IVD, Alzheimer's disease, Pharmaceutical industry, Medical imaging, Medical device

ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer , addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion.

Key Points: 
  • ANAHEIM, Calif., July 25, 2023 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, today revealed for the first time in North America the DxI 9000 Access Immunoassay Analyzer , addressing clinical laboratory demands for speed, reliability, reproducibility, quality, and menu expansion.
  • Early system evaluations and conversations with users suggest that the DxI 9000 Analyzer opens up new opportunities to quantify trace amounts of key biomarkers in blood samples.
  • Initial assay development efforts will focus on the recently introduced DxI 9000 Access Immunoassay Analyzer and the widespread installed base of Access Family Immunoassay Analyzers.
  • The DxI 9000 Access Immunoassay Analyzer is currently available in most countries worldwide.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics

Retrieved on: 
Monday, July 17, 2023
Biotechnology, Other Health, Health, General Health, Mental Health, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Partnership, Apolipoprotein E, Therapy, Prevalence, AFL, Disability, Public, Neurodegenerative disease, ADX, DSM-IV codes, Neurology, Biomarker, Death, Dementia, Fluid mechanics, RUO, Acquisition, Neuroscience, Patient, Laboratory, Beckman, DirectX, Blood, IVD, Immunoassay, CSF, FDA, Beckman Coulter, Disease, Medical imaging, Pharmaceutical industry, Fujirebio

The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving patients‘ health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer’s Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • To complement the current diagnostic solutions, which rely on PET-imaging or a lumbar puncture for cerebral spinal fluid testing, Fujirebio and Beckman Coulter intend to bolster widespread access to patient-friendly, blood-based diagnostic capabilities which will complement and accelerate the impact of breakthrough Alzheimer’s Disease therapeutics.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer’s Disease care.”
    “This collaboration with Beckman Coulter will help accelerate the deployment of our portfolio of new, novel neurodegenerative biomarkers to laboratories and clinicians around the world.

Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test

Retrieved on: 
Monday, July 17, 2023
Beckman Coulter, Partnership, Apolipoprotein E, Therapy, Prevalence, Alzheimer's disease, AFL, Disease, Disability, Public, Neurodegenerative disease, ADX, DSM-IV codes, Research, Neurology, Biomarker, Death, Alzheimer's Disease International, Dementia, Fluid mechanics, RUO, Acquisition, Neuroscience, DirectX, Patient, Laboratory, Beckman, Blood, IVD, Immunoassay, CSF, Health, FDA, Medical imaging, Pharmaceutical industry, Fujirebio

BREA, Calif. and TOKYO, July 17, 2023 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Key Points: 
  • The recent approval by the FDA of two monoclonal antibody-based therapeutics is a major milestone in improving Alzheimer's patients' health and slowing down disease progression.
  • The intersection of the growing prevalence of neurodegenerative disease and advances in disease-modifying therapies for Alzheimer's Disease makes the new Beckman Coulter and Fujirebio partnership evermore critical.
  • We at Beckman Coulter Diagnostics believe access to blood-based tests is critical to Alzheimer's Disease care."
  • The availability of these new biomarkers allows clinical research professionals to further investigate clinical utility in assessing Alzheimer's Disease or other neurological disease conditions.